Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by gebremeskelon Jun 05, 2024 3:19pm
199 Views
Post# 36073803

RE:RE:RE:RE:Well hush my mouth …

RE:RE:RE:RE:Well hush my mouth …Show time is getting ever closer. The second half of 2024 begins in 25 days.

"In the kidney care separation we are very advanced in the dual pathway, which is potential sale of the business to a private equity investor but also a spinoff of the business as a publicly traded company. So we continue to make progress on both fronts and we are actually very advanced in the separation process and we are committed to separating in the second half of 2024."


Accountprince wrote: The difference between the value at time exercised and the exercise price is effectively taxed at 50% up to the first $200K each year for employees and at 100% after that because of the $200K ceiling on deduction for stock options currently in place.  Not clear how the new June 24 rules may affect this as it has a $200K exemption and 66% inclusion rate after that.  I do expect that this has very little to do with tax planning and much more to do events coming up in the very near future.  These guys don't lay out cash until they have to.  I expect some action from Baxter/Vantive/Private equity very soon.  And Paradigm has set $2 plus a share as their current value.  Let's see where we end up.

I think MM's valuations will come into play soon.


<< Previous
Bullboard Posts
Next >>